Dennison E M, Arden N K, Kellingray S, Croft P, Coggon D, Cooper C
MRC Environmental Epidemiology Unit, University of Southampton, Southampton General Hospital.
Br J Rheumatol. 1998 Nov;37(11):1198-202. doi: 10.1093/rheumatology/37.11.1198.
Recent epidemiological studies suggest that post-menopausal hormone replacement therapy might reduce the risk of hip osteoarthritis (OA) in women. However, the association of the disorder with other reproductive variables is controversial. We addressed this issue in a population-based case control study among 413 female cases and 413 age- and sex-matched controls.
A total of 413 women listed for hip replacement because of primary OA over an 18 month period were compared with an equal number of controls selected from the general population and individually matched for age and general practice. Information about reproductive variables was obtained by questionnaire administered at interview.
The risk of hip OA was significantly elevated among women who had had an oophorectomy (OR = 1.9, 95% CI 1.0-3.7). After adjustment for body mass index, the presence of Heberden's nodes, previous hip injury and past leisure sporting activity (all independent risk factors for hip OA), and for other reproductive variables, there was a non-significant, protective effect of long-term hormone replacement therapy, such that > or =5 yr of use was associated with a 40% reduction in risk (OR = 0.6, 95% CI 0.2-1.8). Paradoxically, short-term HRT use (up to 5 yr duration) was associated with an excess risk of hip OA (OR = 1.7, 95% CI 0.9-3.3). There was no association between the risk of hip OA and use of oral contraceptives, parity or hysterectomy.
These data are consistent with previous studies suggesting a protective effect of long-term hormone replacement therapy on the risk of hip OA. By contrast, an elevation of risk in short-term users was demonstrated. Our results also suggest that risk is increased among women who have undergone unilateral or bilateral oophorectomy. Studies are required to investigate the mechanisms underlying these associations.
近期的流行病学研究表明,绝经后激素替代疗法可能会降低女性患髋骨关节炎(OA)的风险。然而,该疾病与其他生殖变量之间的关联存在争议。我们在一项基于人群的病例对照研究中探讨了这一问题,该研究纳入了413例女性病例和413例年龄及性别匹配的对照。
将18个月内因原发性OA而接受髋关节置换手术的413名女性与从普通人群中选取的数量相等的对照进行比较,这些对照在年龄和全科医疗方面进行了个体匹配。通过访谈时发放的问卷获取有关生殖变量的信息。
接受过卵巢切除术的女性患髋OA的风险显著升高(OR = 1.9,95% CI 1.0 - 3.7)。在对体重指数、赫伯登结节的存在、既往髋部损伤和过去的休闲体育活动(均为髋OA的独立危险因素)以及其他生殖变量进行调整后,长期激素替代疗法有非显著的保护作用,即使用≥5年与风险降低40%相关(OR = 0.6,95% CI 0.2 - 1.8)。矛盾的是,短期使用激素替代疗法(使用时间≤5年)与髋OA风险增加相关(OR = 1.7,95% CI 0.9 - 3.3)。髋OA风险与口服避孕药的使用、产次或子宫切除术之间无关联。
这些数据与先前的研究一致,表明长期激素替代疗法对髋OA风险有保护作用。相比之下,短期使用者的风险有所升高。我们的结果还表明,单侧或双侧卵巢切除术后的女性风险增加。需要开展研究来探究这些关联背后的机制。